A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Merus B.V.
Merus B.V.
Boehringer Ingelheim
Ensem Therapeutics
AstraZeneca
Seagen Inc.
Genmab
Seagen Inc.
Fulgent Pharma LLC.
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Johnson & Johnson Enterprise Innovation Inc.
Exelixis
Kivu Bioscience Inc.
EpiBiologics
AstraZeneca
Bicara Therapeutics
STORM Therapeutics LTD
Tubulis GmbH
Eli Lilly and Company
Neonc Technologies, Inc.
Gilead Sciences
Arcus Biosciences, Inc.
Ipsen
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
R-Pharm
R-Pharm
Bristol-Myers Squibb
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer
Merus B.V.
Pfizer
Merus B.V.
Pfizer
Radiopharm Theranostics, Ltd
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Aulos Bioscience, Inc.
Novartis
Genentech, Inc.
ALX Oncology Inc.
AbbVie
Clasp Therapeutics, Inc.
BioNTech SE
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
Poseida Therapeutics, Inc.